Andrew Chi MD PhD
Andrew Chi has served as our Vice President of Clinical Development since October 2021. Andrew is a physician scientist who brings over 15 years of experience in drug development and translational oncology research. Prior to joining Bright Peak, Andrew served as Executive Medical Director at Mirati Therapeutics where he led the clinical development of adagrasib, advancing adagrasib into multiple registrational trials and achieving FDA breakthrough therapy designation in lung cancer. Prior to Mirati, Andrew was Senior Medical Director at Neon Therapeutics where he led the personalized neoantigen vaccine and autologous T cell therapy clinical programs prior to Neon’s acquisition by BioNTech. Prior to entering industry, Andrew served as the Director of Neuro-Oncology and Co-Director of the Brain Tumor Center at the NYU School of Medicine and was on the faculty at Harvard Medical School/Massachusetts General Hospital. As a principal investigator he discovered several new therapeutic targets and a diagnostic imaging biomarker in glioblastoma, authored more than 90 peer-reviewed manuscripts, and published several patents. In addition, Andrew continues to serve as a Senior Editor for Clinical Cancer Research. Andrew received his M.D. and Ph.D. in Biochemistry from the Chicago Medical School and completed neurology residency in the Harvard Medical School program at Massachusetts General Hospital and Brigham and Women’s Hospital, serving as Chief Resident in his final year. He completed a fellowship in neuro-oncology at Dana Farber Cancer Institute/Mass General Cancer Center and a post-doctoral research fellowship at the Broad Institute of MIT and Harvard.